Showing results (351-360 of 1,019) with videos related to

Sort By:
Pageof 102
Clinicoeconomics and Outcomes Research : CEOR|March 20, 2012
Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico CityChristian Díaz de León-Castañeda, Marina Altagracia-Martínez, Jaime Kravzov-Jinich, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 22, 2014
Economic burden associated with chronic constipation in Sweden: a retrospective cohort studySara Bruce Wirta, Paul Hodgkins, Alain Joseph
Clinicoeconomics and Outcomes Research : CEOR|April 30, 2013
Update on the management of cirrhosis - focus on cost-effective preventative strategiesGuy W Neff, Nyingi Kemmer, Christopher Duncan, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 5, 2013
Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groupsRebecca S Campbell, Paresh Chaudhari, Harlen D Hays, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 27, 2013
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycinJennifer M Stephens, Xin Gao, Dipen A Patel, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 8, 2013
Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery deviceMichael Grabner, Yong Chen, Matthew Nguyen, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 10, 2013
Demographics and clinical and economic characteristics of patients receiving total hip arthroplasty with and without muscle atrophy/weaknessNin Wu, Shih-Yin Chen, Yuan-Chi Lee, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 10, 2013
Fluid overload is associated with increases in length of stay and hospital costs: pooled analysis of data from more than 600 US hospitalsGlenn Magee, Art Zbrozek
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 4, 2016
Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single centerMichele Carron, Fabio Baratto, Francesco Zarantonello, et al.
Pageof 102